비교리스트

 카트 문의
시장보고서
상품코드
1400486

세계의 비결핵성 항산균증 시장(2024-2028년)

Global Nontuberculous Mycobacterial Infections Market 2024-2028
발행일: | 리서치사: TechNavio | 페이지 정보: 영문 177 Pages | 배송안내 : 즉시배송

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

개요

비결핵성 항산균증(NTM) 시장은 2023-2028년간 43억 3,000만 달러 확대되고, 예측 기간 중 연평균 복합 성장률(CAGR)은 5.66%를 나타낼 것으로 예측됩니다.

비결핵성 항산균증 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

시장 범위
기준년 2023
종료년 2028
예측 기간 2024-2028
성장 모멘텀 가속
YOY 2024 5.25%
CAGR 5.66%
증분액 43억 3,000만 달러

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. 세계적인 NTM 유병률 증가, 고령자 인구 증가, NTM 감염증에 대한 인식 및 진단 증가 등이 시장 성장을 촉진하고 있습니다.

본 조사에서는 NTM 감염증 치료에 정밀의료를 채택하는 경향이 강해지고 있는 것이 향후 몇 년간 비결핵성 항산균증 시장 성장을 가속하는 주요인 중 하나로 특정하고 있습니다. 신규 약물전달 시스템의 부상이나 병용요법에 대한 주목 증가 또한 시장의 높은 수요로 연결될 전망입니다.

목차

제1장 주요 요약

  • 시장 개요

제2장 시장 구도

  • 시장 생태계

제3장 시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모(2023년)
  • 시장 전망(2023-2028년)

제4장 시장 규모 실적

  • 세계의 비결핵성 항산균증 시장(2018-2022년)
  • 유통 채널별 부문 분석(2018-2022년)
  • 제품별 부문 분석(2018-2022년)
  • 지역별 부문 분석(2018-2022년)
  • 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

  • Five Forces 요약
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 신규 진출업체의 위협
  • 대체품의 위협
  • 경쟁 위협
  • 시장 현황

제6장 시장 세분화 : 유통 채널별

  • 시장 부문
  • 비교 : 유통 채널별
  • 병원 약국 : 시장 규모와 예측(2023-2028년)
  • 소매 약국 : 시장 규모와 예측(2023-2028년)
  • 온라인 약국 : 시장 규모와 예측(2023-2028년)
  • 시장 기회 : 유통 채널별

제7장 시장 세분화 : 제품별

  • 시장 부문
  • 비교 : 제품별
  • Clarithromycin : 시장 규모와 예측(2023-2028년)
  • Azithromycin : 시장 규모와 예측(2023-2028년)
  • Rifampin : 시장 규모와 예측(2023-2028년)
  • Rifabutin : 시장 규모와 예측(2023-2028년)
  • 기타 : 시장 규모와 예측(2023-2028년)
  • 시장 기회 : 제품별

제8장 고객 상황

  • 고객 상황 개요

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 : 시장 규모와 예측(2023-2028년)
  • 유럽 : 시장 규모와 예측(2023-2028년)
  • 아시아 : 시장 규모와 예측(2023-2028년)
  • 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
  • 미국 : 시장 규모와 예측(2023-2028년)
  • 영국 : 시장 규모와 예측(2023-2028년)
  • 일본 : 시장 규모와 예측(2023-2028년)
  • 독일 : 시장 규모와 예측(2023-2028년)
  • 중국 : 시장 규모와 예측(2023-2028년)
  • 시장 기회 : 지역별

제10장 성장 촉진요인, 과제 및 동향

  • 시장 성장 촉진요인
  • 시장이 해결해야 할 과제
  • 성장 촉진요인과 과제의 영향
  • 시장 동향

제11장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란 상황
  • 업계 리스크

제12장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Cipla Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Insmed Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Pfizer Inc.
  • QIAGEN NV
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

제13장 부록

LSH 24.01.10

Abstract

The nontuberculous mycobacterial infections market is forecasted to grow by USD 4.33 bn during 2023-2028, accelerating at a CAGR of 5.66% during the forecast period. The report on the nontuberculous mycobacterial infections market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Market Scope
Base Year2023
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20245.25%
CAGR5.66%
Incremental Value$4.33bn

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of NTM globally, rising geriatric population, and increasing awareness and diagnosis of NTM infections.

Technavio's nontuberculous mycobacterial infections market is segmented as below:

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Product

  • Clarithromycin
  • Azithromycin
  • Rifampin
  • Rifabutin
  • Others

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the growing adoption of precision medicine for treatment of ntm infections as one of the prime reasons driving the nontuberculous mycobacterial infections market growth during the next few years. Also, rise of novel drug delivery systems and growing focus on combination therapies will lead to sizable demand in the market.

The report on the nontuberculous mycobacterial infections market covers the following areas:

  • Nontuberculous mycobacterial infections market sizing
  • Nontuberculous mycobacterial infections market forecast
  • Nontuberculous mycobacterial infections market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading nontuberculous mycobacterial infections market vendors that include Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the nontuberculous mycobacterial infections market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market by Geography
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global nontuberculous mycobacterial infections market 2018 - 2022
  • Exhibit 18: Historic Market Size - Data Table on global nontuberculous mycobacterial infections market 2018 - 2022 ($ billion)
  • 4.2 Distribution Channel Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
  • 4.3 Product Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
  • 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
  • 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

  • 6.1 Market segments
  • Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
  • Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
  • 6.2 Comparison by Distribution Channel
  • Exhibit 32: Chart on Comparison by Distribution Channel
  • Exhibit 33: Data Table on Comparison by Distribution Channel
  • 6.3 Hospital pharmacies - Market size and forecast 2023-2028
  • Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • 6.4 Retail pharmacies - Market size and forecast 2023-2028
  • Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • 6.5 Online pharmacies - Market size and forecast 2023-2028
  • Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • 6.6 Market opportunity by Distribution Channel
  • Exhibit 46: Market opportunity by Distribution Channel ($ billion)
  • Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)

7 Market Segmentation by Product

  • 7.1 Market segments
  • Exhibit 48: Chart on Product - Market share 2023-2028 (%)
  • Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
  • 7.2 Comparison by Product
  • Exhibit 50: Chart on Comparison by Product
  • Exhibit 51: Data Table on Comparison by Product
  • 7.3 Clarithromycin - Market size and forecast 2023-2028
  • Exhibit 52: Chart on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 53: Data Table on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 54: Chart on Clarithromycin - Year-over-year growth 2023-2028 (%)
  • Exhibit 55: Data Table on Clarithromycin - Year-over-year growth 2023-2028 (%)
  • 7.4 Azithromycin - Market size and forecast 2023-2028
  • Exhibit 56: Chart on Azithromycin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 57: Data Table on Azithromycin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 58: Chart on Azithromycin - Year-over-year growth 2023-2028 (%)
  • Exhibit 59: Data Table on Azithromycin - Year-over-year growth 2023-2028 (%)
  • 7.5 Rifampin - Market size and forecast 2023-2028
  • Exhibit 60: Chart on Rifampin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 61: Data Table on Rifampin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 62: Chart on Rifampin - Year-over-year growth 2023-2028 (%)
  • Exhibit 63: Data Table on Rifampin - Year-over-year growth 2023-2028 (%)
  • 7.6 Rifabutin - Market size and forecast 2023-2028
  • Exhibit 64: Chart on Rifabutin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 65: Data Table on Rifabutin - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 66: Chart on Rifabutin - Year-over-year growth 2023-2028 (%)
  • Exhibit 67: Data Table on Rifabutin - Year-over-year growth 2023-2028 (%)
  • 7.7 Others - Market size and forecast 2023-2028
  • Exhibit 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 70: Chart on Others - Year-over-year growth 2023-2028 (%)
  • Exhibit 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
  • 7.8 Market opportunity by Product
  • Exhibit 72: Market opportunity by Product ($ billion)
  • Exhibit 73: Data Table on Market opportunity by Product ($ billion)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 75: Chart on Market share by geography 2023-2028 (%)
  • Exhibit 76: Data Table on Market share by geography 2023-2028 (%)
  • 9.2 Geographic comparison
  • Exhibit 77: Chart on Geographic comparison
  • Exhibit 78: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 9.7 US - Market size and forecast 2023-2028
  • Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
  • 9.8 UK - Market size and forecast 2023-2028
  • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • 9.9 Japan - Market size and forecast 2023-2028
  • Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
  • Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
  • 9.10 Germany - Market size and forecast 2023-2028
  • Exhibit 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 9.11 China - Market size and forecast 2023-2028
  • Exhibit 111: Chart on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 112: Data Table on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 113: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibit 114: Data Table on China - Year-over-year growth 2023-2028 (%)
  • 9.12 Market opportunity by geography
  • Exhibit 115: Market opportunity by geography ($ billion)
  • Exhibit 116: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 117: Impact of drivers and challenges in 2023 and 2028
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 119: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 120: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 121: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 122: Matrix on vendor position and classification
  • 12.3 Abbott Laboratories
  • Exhibit 123: Abbott Laboratories - Overview
  • Exhibit 124: Abbott Laboratories - Business segments
  • Exhibit 125: Abbott Laboratories - Key news
  • Exhibit 126: Abbott Laboratories - Key offerings
  • Exhibit 127: Abbott Laboratories - Segment focus
  • 12.4 Astellas Pharma Inc.
  • Exhibit 128: Astellas Pharma Inc. - Overview
  • Exhibit 129: Astellas Pharma Inc. - Product / Service
  • Exhibit 130: Astellas Pharma Inc. - Key news
  • Exhibit 131: Astellas Pharma Inc. - Key offerings
  • 12.5 Cipla Ltd.
  • Exhibit 132: Cipla Ltd. - Overview
  • Exhibit 133: Cipla Ltd. - Business segments
  • Exhibit 134: Cipla Ltd. - Key news
  • Exhibit 135: Cipla Ltd. - Key offerings
  • Exhibit 136: Cipla Ltd. - Segment focus
  • 12.6 Glenmark Pharmaceuticals Ltd.
  • Exhibit 137: Glenmark Pharmaceuticals Ltd. - Overview
  • Exhibit 138: Glenmark Pharmaceuticals Ltd. - Product / Service
  • Exhibit 139: Glenmark Pharmaceuticals Ltd. - Key offerings
  • 12.7 Hikma Pharmaceuticals Plc
  • Exhibit 140: Hikma Pharmaceuticals Plc - Overview
  • Exhibit 141: Hikma Pharmaceuticals Plc - Business segments
  • Exhibit 142: Hikma Pharmaceuticals Plc - Key offerings
  • Exhibit 143: Hikma Pharmaceuticals Plc - Segment focus
  • 12.8 Insmed Inc.
  • Exhibit 144: Insmed Inc. - Overview
  • Exhibit 145: Insmed Inc. - Product / Service
  • Exhibit 146: Insmed Inc. - Key offerings
  • 12.9 Johnson and Johnson
  • Exhibit 147: Johnson and Johnson - Overview
  • Exhibit 148: Johnson and Johnson - Business segments
  • Exhibit 149: Johnson and Johnson - Key news
  • Exhibit 150: Johnson and Johnson - Key offerings
  • Exhibit 151: Johnson and Johnson - Segment focus
  • 12.10 Lupin Ltd.
  • Exhibit 152: Lupin Ltd. - Overview
  • Exhibit 153: Lupin Ltd. - Product / Service
  • Exhibit 154: Lupin Ltd. - Key news
  • Exhibit 155: Lupin Ltd. - Key offerings
  • 12.11 Pfizer Inc.
  • Exhibit 156: Pfizer Inc. - Overview
  • Exhibit 157: Pfizer Inc. - Product / Service
  • Exhibit 158: Pfizer Inc. - Key news
  • Exhibit 159: Pfizer Inc. - Key offerings
  • 12.12 QIAGEN NV
  • Exhibit 160: QIAGEN NV - Overview
  • Exhibit 161: QIAGEN NV - Product / Service
  • Exhibit 162: QIAGEN NV - Key news
  • Exhibit 163: QIAGEN NV - Key offerings
  • 12.13 Sanofi SA
  • Exhibit 164: Sanofi SA - Overview
  • Exhibit 165: Sanofi SA - Business segments
  • Exhibit 166: Sanofi SA - Key news
  • Exhibit 167: Sanofi SA - Key offerings
  • Exhibit 168: Sanofi SA - Segment focus
  • 12.14 Sun Pharmaceutical Industries Ltd.
  • Exhibit 169: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibit 170: Sun Pharmaceutical Industries Ltd. - Product / Service
  • Exhibit 171: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 12.15 Teva Pharmaceutical Industries Ltd.
  • Exhibit 172: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 176: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 12.16 Viatris Inc.
  • Exhibit 177: Viatris Inc. - Overview
  • Exhibit 178: Viatris Inc. - Business segments
  • Exhibit 179: Viatris Inc. - Key news
  • Exhibit 180: Viatris Inc. - Key offerings
  • Exhibit 181: Viatris Inc. - Segment focus
  • 12.17 Zydus Lifesciences Ltd.
  • Exhibit 182: Zydus Lifesciences Ltd. - Overview
  • Exhibit 183: Zydus Lifesciences Ltd. - Business segments
  • Exhibit 184: Zydus Lifesciences Ltd. - Key offerings
  • Exhibit 185: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 186: Inclusions checklist
  • Exhibit 187: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 188: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 189: Research methodology
  • Exhibit 190: Validation techniques employed for market sizing
  • Exhibit 191: Information sources
  • 13.5 List of abbreviations
  • Exhibit 192: List of abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제